[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Insulin Pumps and Continuous Glucose Monitors (Diabetes Care Devices) - Global Market Analysis and Forecast Model

January 2020 | | ID: I451F30ADC6EEN
GlobalData

US$ 7,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Insulin Pumps and Continuous Glucose Monitors (Diabetes Care Devices) - Global Market Analysis and Forecast Model

SUMMARY

Insulin Pumps and Continuous Glucose Monitors (Diabetes Care Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Diabetes Care Devices therapeutic area.

Diabetes mellitus is a worldwide epidemic disease. Globally, diabetes prevalence is estimated to be 9.3% in 2019 and will rise to 10.2% by 2030 and 10.9% by 2045. Urban population has higher prevalence (10.8%) than rural population (7.2%), and prevalence of high-income countries (10.4%) is more than low-income countries (4.0%). One in two people living with diabetes are undiagnosed. International Diabetes Federation (IDF) has reported that in 2009 it was estimated that 285 million people had diabetes, including both type 1 and type 2 which increased to 366 million in 2011 and 425 million in 2017. The report has projected that number of cases of diabetes will increase to 578 million in 2030.

There are three types of diabetes based on insulin production in the body. They are Type 1 (Juvenile diabetes) and Type 2 (Adult diabetes) and gestational diabetes (which occur mostly among pregnant women). Type 1 diabetes accounts for 5% to 10% of the diagnosed cases of whereas, type 2 accounts for 90% to 95% and less than 1% are the rarer types of diabetes.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the Market Model

Currently marketed Insulin Pumps and Continuous Glucose Monitors and evolving competitive landscape -
  • Insightful review of the key industry trends.
  • Annualized total Insulin Pumps and Continuous Glucose Monitors market revenue by segment and market outlooks from 2015–2028.
  • Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Insulin Pumps and Continuous Glucose Monitors market.
  • Competitive dynamics insights and trends provided for Insulin Pumps and Continuous Glucose Monitors market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic plc, Dexcom Inc, Abbott Laboratories, Ypsomed Holding AG, Tandem Diabetes Care Inc, F. Hoffmann-La Roche Ltd, Insulet Corp, Valeritas Inc, Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

SCOPE

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the Insulin Pumps and Continuous Glucose Monitors marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
REASONS TO BUY

The model will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Insulin Pumps and Continuous Glucose Monitors market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Insulin Pumps and Continuous Glucose Monitors market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Insulin Pumps and Continuous Glucose Monitors market from 2015-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


COMPANIES MENTIONED

Medtronic plc
Dexcom Inc
Abbott Laboratories
Ypsomed Holding AG
Tandem Diabetes Care Inc
F. Hoffmann-La Roche Ltd
Insulet Corp
Valeritas Inc

The insulin pumps and continuous glucose monitors (CGM) market in the Asia-Pacific (APAC) region is expected to grow at a compound annual growth rate (CAGR) of 4.4% from US$0.9bn in 2019 to US$1.4bn by 2028, according to GlobalData, a leading data and analytics company.

Japan will be by far the fastest growing country in the region growing at a CAGR of 6.1% between 2019 and 2028, which is closely followed by India and China, respectively.

The company’s report, ‘Insulin Pumps and Continuous Glucose Monitors - Diabetes Care Devices Market Analysis and Forecast Model’ states that while rapid increase in the prevalence of diabetes will be the main market driver, government initiatives such as introduction of reimbursement policies will play a major role in propelling the market during the forecast period.

Manasa, Medical Devices Analyst at GlobalData, comments: “Medtronic has retained its position as the market leader in the APAC due to its innovation of advanced technologies by acknowledging the requirements of the patients and establishing collaborative agreements. The local manufacturers also have good scope of gaining a significant share in the market but will have to face a tough competition against the already existing players.”

Insulet Corporation and Valeritas Inc have globally established themselves as sole players in the market for programmable insulin patch pumps and non-programmable insulin patch pumps, respectively.

Manasa concludes: “The technological advancements in the medical field will have a positive impact on the growth of insulin pumps & CGM market. Easy administration and increased lifespan of the sensor will drive the market for insulin pumps and CGM respectively in the forecast period.”



More Publications